KAM
Krensavage Asset Management Portfolio holdings
AUM
$189M
This Quarter Return
-8.27%
1 Year Return
+19.71%
3 Year Return
+56.44%
5 Year Return
+120.01%
10 Year Return
+215.64%
AUM
$314M
AUM Growth
+$314M
(-15%)
Cap. Flow
-$19.2M
Cap. Flow
% of AUM
-6.11%
Top 10 Holdings %
Top 10 Hldgs %
99.44%
Holding
11
New
–
Increased
6
Reduced
5
Closed
–
Top Buys
| 1 |
Enanta Pharmaceuticals
ENTA
|
$2.85M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$1.44M |
| 3 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
$871K |
| 4 |
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
|
$723K |
| 5 |
Alkermes
ALKS
|
$128K |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$11.1M |
| 2 |
United Therapeutics
UTHR
|
$4.68M |
| 3 |
McKesson
MCK
|
$4.48M |
| 4 |
Biogen
BIIB
|
$4.04M |
| 5 |
AnaptysBio
ANAB
|
$973K |
Sector Composition
| 1 | Healthcare | 97.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Regeneron Pharmaceuticals
REGN
$61.5B
| $46M | 14.66% | 82,258 +2,567 | +3% | +$1.44M |
|
|
ALXN
2
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $45.4M | 14.45% | 396,575 -96,595 | -20% | -$11.1M |
|
|
3
United Therapeutics
UTHR
$13.8B
| $43M | 13.71% | 426,215 -46,333 | -10% | -$4.68M |
|
|
4
Biogen
BIIB
$19.4B
| $38.9M | 12.39% | 137,163 -14,257 | -9% | -$4.04M |
|
|
5
Enanta Pharmaceuticals
ENTA
$180M
| $37.8M | 12.03% | 825,329 +62,226 | +8% | +$2.85M |
|
|
TARO
6
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $29.5M | 9.38% | 537,378 +15,871 | +3% | +$871K |
|
|
7
McKesson
MCK
$85.4B
| $27.7M | 8.82% | 186,030 -30,112 | -14% | -$4.48M |
|
|
8
Alkermes
ALKS
$4.78B
| $26.1M | 8.3% | 1,572,395 +7,730 | +0.5% | +$128K |
|
|
SRGA
9
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $11.3M | 3.6% | 6,251,208 +399,636 | +7% | +$723K |
|
|
IVC
10
DELISTED
Invacare Corporation
IVC
| $6.63M | 2.11% | 880,920 +4,499 | +0.5% | +$33.8K |
|
|
11
AnaptysBio
ANAB
$569M
| $1.75M | 0.56% | 118,858 -65,988 | -36% | -$973K |
|